The glucagon-like peptide 1 receptor (GLP-1R) analog semaglutide, a once-weekly injectable medication for type 2 diabetes mellitus and obesity [37], targets the circumventricular organs rather than permeating the blood-brain barrier. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.